Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Discover surprising risk factors for type 2 diabetes beyond diet and weight. Learn about hidden triggers that could increase ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: ...

“Having a new and effective steroid-free option, without some of the risks associated with topical and systemic steroids ... short-term and non-continuous chronic treatment of adults and ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Cat pooping and vomiting can be alarming. Find out the causes and solutions to help your cat recover with our comprehensive ...

UPDATE | Olorato Mongale murder: Cops hunting for third suspect after finding car in KZN Zimbabwean organisation pleads forgiveness following deadly attacks in Eastern Cape Witness in Zandile Gumede ...